Find Trials Near
Speak with a clinical trials expert
Have multiple conditions? Click here

Irritable Bowel Syndrome (IBS) Clinical Trials

New Clinical Trials for Irritable Bowel Syndrome (IBS)

Enroll in a Clinical Trial for Irritable Bowel SyndromeIf you suffer from irritable bowel syndrome chances are you spend many days being uncomfortable and missing work because of your condition. Although there is a large body of irritable bowel syndrome clinical research, not much is known about the disease.

While some suspect it is the result of a yet to be discovered infection others believe there is a mind/body connection. There is no known cause, no clear diagnosis method and no cure. There are ongoing irritable bowel syndrome clinical trials being conducted. 

What is Irritable Bowel Syndrome (IBS)?

Irritable bowel syndrome (IBS) is also sometimes called spastic colon. Irritable bowel syndrome is diagnosed when no specific cause can be found for a condition that involves chronic pain in the abdomen, bloating and abnormal bowel habits. There are several classifications of IBS – constipation predominant (IBS-C), diarrhea predominant (IBS-D) and alternating between the two (IBS-A). The cause of irritable bowel syndrome is not known. Some believe it is a disorder where the brain and the gastrointestinal tract have trouble communicating cheap valium order buy valium online usa order valium america . Others believe it is a psychological disease resulting from stress.

Irritable Bowel Syndrome (IBS) Treatments

Irritable bowel syndrome was first documented as such around 1950. Many tests have been done on diet and how this might affect a person suffering from IBS. In some patients restricting their diet of lactose or fructose has helped in treating irritable bowel syndrome. Taking in more soluble fiber has also proven effective. Depending on the type of IBS different medications like laxatives or antispasmodics can be prescribed. Psychotherapy including cognitive behavior therapy and hypnosis has been effective in treating irritable bowel syndrome. As a last resort for the treatment of irritable bowel syndrome tricyclic antidepressants are sometimes prescribed.

NEW Early Serum Infliximab Levels in Severe Ulcerative Colitis.

San Francisco
California
94122
Age: 18 - Any
Conditions: Colitis, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW Self-Management Assistance for Recommended Treatment (SMART) Portal

Cincinnati
Ohio
45229
Age: 11 - 18
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW Self-Management Assistance for Recommended Treatment (SMART) Portal

Charlottesville
Virginia
22901
Age: 11 - 18
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease

Austin
Texas
78723
Age: 8 - 18
Conditions: Digestive Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)

Durham
North Carolina
Age: Any
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW OPERA Database - Crohn's Protocol

Lebanon
New Hampshire
03756
Age: 18 - Any
Conditions: Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW IBD-OPERA Database, UC Protocol

Lebanon
New Hampshire
03756
Age: 18 - Any
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Chattanooga
Tennessee
Age: 18 - 75
Conditions: Constipation, Irritable Bowel Syndrome (IBS)

NEW The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Winston-Salem
North Carolina
Age: 18 - 75
Conditions: Constipation, Irritable Bowel Syndrome (IBS)

NEW The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Boulder
Colorado
80304
Age: 18 - 75
Conditions: Constipation, Irritable Bowel Syndrome (IBS)

NEW The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Greensboro
North Carolina
27401
Age: 18 - 75
Conditions: Constipation, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Miami
Florida
33144
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Columbus
Ohio
43215
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Miami
Florida
33015
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

La Mesa
California
91942
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Phoenix
Arizona
85018
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

St. Louis
Missouri
63141
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Winston-Salem
North Carolina
27103
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

St. Petersburg
Florida
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Watertown
Massachusetts
02472
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

San Antonio
Texas
78258
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Encino
California
91436
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Santa Ana
California
92701
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Las Vegas
Nevada
89119
Age: 18 - 75
Conditions: Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

Rochester
Minnesota
55905
Age: 18 - 65
Conditions: Digestive Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS), Pain

NEW Stress Management for Irritable Bowel Syndrome

Detroit
Michigan
48201
Age: 18 - 70
Conditions: Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Boston
Massachusetts
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Portland
Oregon
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Philadelphia
Pennsylvania
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Phoenix
Arizona
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Baltimore
Maryland
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Aurora
Colorado
80045
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Indianapolis
Indiana
46202
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Seattle
Washington
98105
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Birmingham
Alabama
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Cleveland
Ohio
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Louisville
Kentucky
40202
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

New York
New York
10032
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Milwaukee
Wisconsin
53226
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lebanon
New Hampshire
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chattanooga
Tennessee
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Salt Lake City
Utah
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Henderson
Nevada
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Jackson
Mississippi
39216
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Dallas
Texas
75390
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)

NEW A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Norfolk
Virginia
23507
Age: 18 - Any
Conditions: Colitis, Crohns Disease, Gastrointestinal, Irritable Bowel Syndrome (IBS)
Return to Search Results
Updating search results
One moment     loading
BROWSE CLINICAL TRIALS BY STATE
Alabama - Alaska - Arizona - Arkansas - California - Colorado - Connecticut - Delaware - Washington DC - Florida - Georgia - Hawaii - Idaho - Illinois - Indiana - Iowa - Kansas - Kentucky - Louisiana - Maine - Maryland - Massachusetts - Michigan - Minnesota - Mississippi - Missouri - Montana - Nebraska - Nevada - New Hampshire - New Jersey - New Mexico - New York - North Carolina - North Dakota - Ohio - Oklahoma - Oregon - Pennsylvania - Rhode Island - South Carolina - South Dakota - Tennessee - Texas - Utah - Vermont - Virginia - Washington - West Virginia - Wisconsin - Wyoming
Copyright 2014 Clinical Trials GPS | All Rights Reserved



Forgot Password?